Why the study?
Does Trimethylamine N-Oxide (TMAO) predict mortality risk and long-term adverse events in patients with peripheral artery disease?
Population
Patients with peripheral artery disease (PAD) with or without significant coronary artery disease
Design
Cohort
Authors
Loading...
May refine PAD risk stratification; hypothesis-generating and should not yet change practice.
Does Trimethylamine N-Oxide (TMAO) predict mortality risk and long-term adverse events in patients with peripheral artery disease?
TMAO levels may help identify high-risk PAD patients who require more aggressive dietary and pharmacologic therapy.
Senthong et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: